MSAAI

BioCryst will attend the 2026 MSAAI on June 06, 2026.

European Academy of Allergy and Clinical Immunology (EAACI) Congress

BioCryst will attend the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Congress from June 12 – June 15, 2026.

  • BQHP010_SID26 SAD MAD BCX17725_Poster_8May26_FINAL
    SID | 2026 | NS
  • BQHP011_SID26 Preclinical BCX17725_Poster_8May26_FINAL
    SID | 2026 | NS
  • Long-Term, Sustained, Robust Hereditary Angioedema Attack Suppression with Navenibart Administered Every 3 and 6 Months: ALPHA-SOLAR Interim Results
    AAAAI | 2026 | HAE
  • Navenibart Demonstrates Durable Efficacy and Tolerability Across Biological Sexes: Subgroup Analysis from the ALPHA-STAR Trial
    AAAAI | 2026 | HAE
  • Navenibart Delays Time to First Attack in Hereditary Angioedema: Results from ALPHA-STARĀ 
    AAAAI | 2026 | HAE

Have questions about any of our medicines that are approved or in development, or would you like to be connected with an MSL?

Have questions about our company?